These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
470 related articles for article (PubMed ID: 16436726)
1. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Andes D; Safdar N; Marchillo K; Conklin R Antimicrob Agents Chemother; 2006 Feb; 50(2):674-84. PubMed ID: 16436726 [TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624 [TBL] [Abstract][Full Text] [Related]
3. Effects of amphotericin B incorporated into liposomes and in lipid suspensions in the treatment of murine candidiasis. Kretschmar M; Nichterlein T; Hannak D; Hof H Arzneimittelforschung; 1996 Jul; 46(7):711-5. PubMed ID: 8842344 [TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Andes D; Stamsted T; Conklin R Antimicrob Agents Chemother; 2001 Mar; 45(3):922-6. PubMed ID: 11181381 [TBL] [Abstract][Full Text] [Related]
5. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B. Smith PJ; Olson JA; Constable D; Schwartz J; Proffitt RT; Adler-Moore JP J Antimicrob Chemother; 2007 May; 59(5):941-51. PubMed ID: 17400589 [TBL] [Abstract][Full Text] [Related]
6. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574 [TBL] [Abstract][Full Text] [Related]
7. Influence of fungicidal activity against Candida tropicalis on the efficacy of micafungin and liposomal amphotericin B in a neutropenic murine lethal infection model. Takemoto K; Nakayama T; Kanazawa K; Ueda Y Pharmacology; 2012; 90(3-4):133-45. PubMed ID: 22847175 [TBL] [Abstract][Full Text] [Related]
8. In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin. Lewis RE; Wiederhold NP; Prince RA; Kontoyiannis DP J Antimicrob Chemother; 2006 Feb; 57(2):288-93. PubMed ID: 16387749 [TBL] [Abstract][Full Text] [Related]
9. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model. Khan MA; Owais M J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B. Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826 [TBL] [Abstract][Full Text] [Related]
11. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation. Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313 [TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. Groll AH; Giri N; Petraitis V; Petraitiene R; Candelario M; Bacher JS; Piscitelli SC; Walsh TJ J Infect Dis; 2000 Jul; 182(1):274-82. PubMed ID: 10882607 [TBL] [Abstract][Full Text] [Related]
13. Amphotericin B formulations: a comparative review of efficacy and toxicity. Hamill RJ Drugs; 2013 Jun; 73(9):919-34. PubMed ID: 23729001 [TBL] [Abstract][Full Text] [Related]
14. Efficacies of amphotericin B (AMB) lipid complex, AMB colloidal dispersion, liposomal AMB, and conventional AMB in treatment of murine coccidioidomycosis. González GM; Tijerina R; Najvar LK; Bocanegra R; Rinaldi MG; Graybill JR Antimicrob Agents Chemother; 2004 Jun; 48(6):2140-3. PubMed ID: 15155212 [TBL] [Abstract][Full Text] [Related]
15. Corneal concentrations following systemic administration of amphotericin B and its lipid preparations in a rabbit model. Goldblum D; Rohrer K; Frueh BE; Theurillat R; Thormann W; Zimmerli S Ophthalmic Res; 2004; 36(3):172-6. PubMed ID: 15103209 [TBL] [Abstract][Full Text] [Related]
16. Tolerance to amphotericin B in clinical isolates of Candida tropicalis. Barchiesi F; Maracci M; Baldassarri I; Spreghini E; Giannini D; Scalise G Diagn Microbiol Infect Dis; 2004 Nov; 50(3):179-85. PubMed ID: 15541603 [TBL] [Abstract][Full Text] [Related]
17. Pulmonary extraction and accumulation of lipid formulations of amphotericin B. Matot I; Pizov R Crit Care Med; 2000 Jul; 28(7):2528-32. PubMed ID: 10921589 [TBL] [Abstract][Full Text] [Related]
18. Efficient treatment of murine systemic infection with Candida albicans using amphotericin B incorporated in nanosize range particles (emulsomes). Kretschmar M; Amselem S; Zawoznik E; Mosbach K; Dietz A; Hof H; Nichterlein T Mycoses; 2001; 44(7-8):281-6. PubMed ID: 11714063 [TBL] [Abstract][Full Text] [Related]
19. Biliary amphotericin B pharmacokinetics and pharmacodynamics in critically ill liver transplant recipients receiving treatment with amphotericin B lipid formulations. Welte R; Eschertzhuber S; Weiler S; Leitner-Rupprich S; Aigner M; Lass-Flörl C; Stienecke E; Bellmann-Weiler R; Joannidis M; Bellmann R Int J Antimicrob Agents; 2015 Sep; 46(3):325-31. PubMed ID: 26119497 [TBL] [Abstract][Full Text] [Related]
20. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Cannon JP; Garey KW; Danziger LH Pharmacotherapy; 2001 Sep; 21(9):1107-14. PubMed ID: 11560200 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]